以雙磷酸鹽藥物治療骨骼轉移
Bisphosphonates in the Treatment of Skeletal Metqastases
Semin Oncol 31:59-63 ...繼續閱讀

於選擇過之轉移乳癌病人進行治癒性手術 ...繼續閱讀

1.
[1074] Long term survival with no apparent toxicity observed with a novel cispla
tin-incorporated polymeric micelle, NC-6004, in the MCF-7 breast cancer model.
NC-6004用於MCF-7乳癌模型達至長期存活且無明顯副作用
2.
[1079] A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer.
scutellaria barbata (BZL101)用於轉移乳癌病人的第一期試驗 ...繼續閱讀

1.
一種口服的抗血管新生藥物－－AG-013736－－與docetaxel併用，對於轉移乳癌病人的效果
[1067] A phase I/II study of AG-013736, an oral anti-angiogenesis agent, in comb
ination with docetaxel in patients (pts) with metastatic breast cancer (MBC).
2.
併用lapatinib (GW572016）與Herceptin治療乳癌病人的安全性，耐受性，以及藥物動力學
[1073] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. ...繼續閱讀

1. [1081] A phase I/II study of capecitabine (X) combined with oral vinorelbine (N) as first- or second-line chemotherapy in patients (pts) with locally advanced breast cancer (MBC).
併用口服截瘤達與vinorelbine對於晚期或轉移乳癌病人的效果


2. A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Breast Cancer
Journal of the Japanese Breast Cancer Society Vol. 13 No.1 January 2006
截瘤達用於晚期或轉移乳癌病人的試驗


...繼續閱讀

[1070] A phase 2b multicenter evaluation of the safety and efficacy of TOCOSOL paclitaxel (TOC- P) as initial treatment of patients with metastatic breast cancer (MBC).
TOCOSOL paclitaxel (TOC- P)作為轉移乳癌病人之第一線治療的安全與藥效之評估

[1066] Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC).
SU11248於曾接受過多種治療的轉移乳癌病人的效果
...繼續閱讀

Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Bortezomib併用截瘤達用於曾接受過紫杉醇類藥物與或是 anthracycline 類藥物治療的轉移乳癌病人
...繼續閱讀

1.
SABCS: ABSTRACT: [1063] E7389, A Novel Anti-Tubulin, is Safe and Effective in Patients with Refractory Breast Cancer
[San Antonio Breast Cancer Symposium]
E7389，一種新的抗微管蛋白藥物，對於治療無效的乳癌的效果



2.ABSTRACT: Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins
標靶式細胞毒殺性藥物 AN-215 可以有效壓制動物實驗中的乳癌，而不致顯著誘發多重抗藥性蛋白質
Endocr Relat Cancer.2005; 12: 999-1009.


...繼續閱讀

1.
SABCS: ABSTRACT: [3] A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100)
比較單用paclitaxel與併用paclitaxel+bevacixumab作為局部復發或轉移乳癌病人之第一線治療的效果
2.
SABCS: ABSTRACT: [2030] A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer
[San Antonio Breast Cancer Symposium]
併用letrozole+bevacizumab於荷爾蒙受體陽性的轉移乳癌病人之第二期試驗 ...繼續閱讀

於曾接受過多種治療的轉移乳癌病人單用 gemcitabine 治療的效果
Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer
Breast Cancer Research and Treatment (2005) 90:215-221
...繼續閱讀